Charles Breen, MD
Ophthalmology · Florence, KYNPI 1437151719
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,070 of the $8,064 with a category attached, or 87.7%. 22 manufacturers reported payments, led by Alcon at 30.6% of the total. Among ophthalmology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$988
- Sun Pharmaceutical Industries Inc.$939
- Bausch & Lomb Americas Inc.$877
- Novartis$633
- Oyster Point Pharma, Inc.$351
- plus $2K from 16 others
What the payments were for
- Travel & lodging$90511%
- Food & beverage$7,07088%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 58 | $2,465 |
| AbbVie(2 entities) | 59 | $988 |
| Sun Pharmaceutical Industries Inc. | 50 | $939 |
| Bausch & Lomb Americas Inc. | 48 | $877 |
| Novartis | 57 | $633 |
| Oyster Point Pharma, Inc. | 17 | $351 |
| Regeneron Healthcare Solutions, Inc. | 11 | $319 |
| Tarsus Pharmaceuticals, Inc. | 5 | $227 |
| Shire North American Group Inc | 9 | $208 |
| Glaukos Corporation | 3 | $181 |
| Aerie Pharmaceuticals, Inc. | 7 | $147 |
| Rxsight Inc | 1 | $121 |
| Eyevance Pharmaceuticals LLC | 7 | $109 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $103 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $91 |
| Kala Pharmaceuticals, Inc. | 4 | $79 |
| Harrow Eye, LLC | 2 | $59 |
| Dompe US, Inc. | 2 | $43 |
| Thea Pharma Inc. | 2 | $40 |
| Amgen(2 entities) | 2 | $34 |
| Genentech USA, Inc. | 1 | $29 |
| Biotissue Holdings Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$1,020
- Centurion$905
- Clareon$905
- LenSx$242
- XDEMVY$150
- Unity$129
- iStent inject W$127
- IACCESS$127
- CEQUA$123
- RXSIGHT CONTACT LENS$121
- RXSIGHT INJECTOR CARTRIDGE$121
- RXSIGHT INJECTOR HANDPIECE$121
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$121
- LIGHT ADJUSTABLE LENS (LAL)$121
How this compares
$8,064 in reported general payments places this provider in the 90th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 276 | $312,804 |
| RestasisCyclosporine | 231 | $284,702 |
| LumiganBimatoprost | 234 | $108,857 |
| CequaCyclosporine | 71 | $63,091 |
| Cyclosporine | 59 | $50,132 |
| MieboPerfluorohexyloctane/Pf | 53 | $42,651 |
| RocklatanNetarsudil Mesylat/Latanoprost | 65 | $30,716 |
| VyzultaLatanoprostene Bunod | 43 | $21,185 |
| Restasis MultidoseCyclosporine | 28 | $17,988 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $6,032 |
| Prednisolone Acetate | 169 | $5,567 |
| CombiganBrimonidine Tartrate/Timolol | 18 | $4,904 |
| Bromfenac Sodium | 22 | $4,377 |
| Travoprost | 16 | $2,301 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $2,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose, Combigan | $988 | $416,452511 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $877 | $376,640372 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $939 | $63,09171 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $147 | $30,71665 claims |
| AlconSimbrinza | $2,465 | $6,03227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Florence
- Zegary AllenFlorence$8K
- Edward HollandEdgewood$678K
- Gary WortzLexington$159K
- Jeremy ClarkLouisville$131K
- Bruce KofflerLexington$49K
- Guruprasad PattarLouisville$36K
- Jeffery TaylorPaducah$18K
- Asim PirachaLexington$17K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.